Navigation Links
AMT Starts Preregistration Trial for Glybera(TM)
Date:5/6/2009

AMSTERDAM, May 7 /PRNewswire-FirstCall/ -- Amsterdam Molecular Therapeutics (Euronext: AMT), a leader in the field of human gene therapy, announced today the treatment of the first patient in a preregistration clinical trial with Glybera(TM). This gene therapy product targets lipoprotein lipase deficiency (LPLD), a seriously debilitating and potentially lethal disease.

The randomized controlled trial has been designed to gather additional data on the effects of Glybera on lipid metabolism and the mechanisms underlying the prevention of pancreatitis attacks. The trial is being performed under a Clinical Trial Application approved by Health Canada.

The new clinical trial builds on positive data obtained from two previous clinical trials in which a total of 22 LPLD patients were treated. These data indicate that a single treatment with Glybera results in a long-term, statistically significant and clinically important reduction in the incidence of acute pancreatitis in LPLD patients. The longest follow-up of individual patients is well over three years, and the cumulative follow-up of all patients is more than 45 years. The therapy was well tolerated and no drug-related severe adverse events or unexpected side-effects have been observed.

AMT will include the data from the new trial in the Marketing Authorization Application for Glybera. The submission of the dossier to the European Medicines Agency is planned for the second half of 2009.

About the Disease

LPLD is an orphan disease, for which no treatment exists today. The disease is caused by mutations in the LPL gene, resulting in highly decreased or absent activity of LPL protein in patients. This protein is needed in order to break down large fat-carrying particles that circulate in the blood after each meal. When such particles, called chylomicrons, accumulate in the blood, they may obstruct small blood vessels. T
'/>"/>

SOURCE Amsterdam Molecular Therapeutics B.V
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. Pierre Fabre Dermatologie Starts Clinical Trials on a Beta-Blocker to Treat Severe Infantile Haemangioma
2. BioCis Pharma Starts Phase IIa Trial in Psoriasis
3. The Pittsburgh Life Sciences Greenhouse Starts 2009 With Investment Momentum
4. China Sky One Medical, Inc. Starts Production at Newly Acquired Facility and Reaffirms Guidance
5. Oncolytics Biotech Inc. Starts Patient Enrolment in U.S. Phase 2 Clinical Trial Investigating REOLYSIN(R) in Combination with Paclitaxel and Carboplatin
6. Gerresheimer Starts Process to Sell off its Business Segment of Technical Plastics
7. Roche starts acquisition process of ARIUS to gain access to new screening platform for antibody therapeutics
8. AMT Starts Collaboration With St. Jude Childrens Research Hospital on Gene Therapy for Hemophilia B. Company Accesses Exclusive Commercial Rights to Final Therapy
9. Anesiva Launches Needle-Free Zingo(TM) to Reduce Pain from IV Starts and Blood Draws in Children
10. Oncolytics Biotech Inc. Starts Patient Enrolment in U.K. Phase II Clinical Trial Investigating REOLYSIN(R) in Combination with Paclitaxel and Carboplatin
11. Oncolytics Biotech Inc. Starts Patient Enrolment in U.K. Combination REOLYSIN(R)/Cyclophosphamide Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... 24, 2013 Die Übersetzungen wurden ... Bei der englischen Version handelt es ... % der Teilnehmer einer groß angelegten Asthmaumfrage halten ihren ... GINA [*] -Definition [1] als kontrolliert gelten können ... generell einer von vier Denkweisen zugeordnet werden können, die ...
(Date:5/23/2013)... stopped breathing, his collapsed bronchus blocking the crucial flow ... watched helplessly, just praying that somehow the dire predictions ... had a good chance of not leaving the hospital ... Kaiba. "At that point, we were desperate. Anything that ... it." , They found hope at the University of ...
(Date:5/23/2013)... Colo. , May 23, 2013 Venaxis, ... diagnostic company focused on obtaining FDA clearance and commercializing ... today announced the pricing of an underwritten public offering ... warrants to purchase 3,500,000 shares of its common stock ... a combined public offering price of $1.25 per share ...
(Date:5/23/2013)... , May 23, 2013  BioScrip, Inc. (NASDAQ: ... will present at the Jefferies 2013 Global Healthcare Conference ... Hyatt New York. Richard Smith ... Hai Tran , Chief Financial Officer, will ... Eastern Daylight Time.   About BioScrip ...
Breaking Biology Technology:Neue Forschungsergebnisse zeigen Verbindung zwischen suboptimaler Asthmaversorgung und Patienteneinstellungen in Europa auf 2Neue Forschungsergebnisse zeigen Verbindung zwischen suboptimaler Asthmaversorgung und Patienteneinstellungen in Europa auf 3Neue Forschungsergebnisse zeigen Verbindung zwischen suboptimaler Asthmaversorgung und Patienteneinstellungen in Europa auf 4Neue Forschungsergebnisse zeigen Verbindung zwischen suboptimaler Asthmaversorgung und Patienteneinstellungen in Europa auf 5Neue Forschungsergebnisse zeigen Verbindung zwischen suboptimaler Asthmaversorgung und Patienteneinstellungen in Europa auf 6Neue Forschungsergebnisse zeigen Verbindung zwischen suboptimaler Asthmaversorgung und Patienteneinstellungen in Europa auf 7Baby's life saved with groundbreaking 3-D printed device that restored his breathing 2Baby's life saved with groundbreaking 3-D printed device that restored his breathing 3Venaxis Announces Pricing of Offering of Common Stock and Warrants 2Venaxis Announces Pricing of Offering of Common Stock and Warrants 3
... who have been dreaming of mobile devices that run ... wish has been granted. University of Illinois engineers ... is faster and uses 100 times less energy than ... devices much longer battery life between charges. Led ...
... Inc. (Nasdaq: MYL ) today announced that ... from the U.S. Food and Drug Administration (FDA) under ... its New Drug Application (NDA) for Zidovudine Tablets, 100 ... drug Retrovir® Tablets, by ViiV Healthcare. This pediatric antiretroviral ...
... (Nasdaq CM: INSMD), a biopharmaceutical company, today reported results ... 2010. Key Recent Highlights: ... 2011 with the FDA to begin a phase 3 ... non-TB Mycobacteria (NTM) lung infections. Successfully concluded 72 ...
Cached Biology Technology:New technology would dramatically extend battery life for mobile devices 2New technology would dramatically extend battery life for mobile devices 3Mylan's Matrix Receives FDA Approval Under PEPFAR for Zidovudine Tablets, 100 mg 2Insmed Announces Fourth Quarter and Full-Year 2010 Financial Results 2Insmed Announces Fourth Quarter and Full-Year 2010 Financial Results 3Insmed Announces Fourth Quarter and Full-Year 2010 Financial Results 4Insmed Announces Fourth Quarter and Full-Year 2010 Financial Results 5Insmed Announces Fourth Quarter and Full-Year 2010 Financial Results 6Insmed Announces Fourth Quarter and Full-Year 2010 Financial Results 7Insmed Announces Fourth Quarter and Full-Year 2010 Financial Results 8
(Date:5/23/2013)... Frontiers in Plant Science , ... gene content and promoter evolution among grasses , ... of stretches of DNA that undergo little change in ... not code for any proteins. Some of these evolutionarily ... to regulate the expression of other genes or the ...
(Date:5/23/2013)... fruit, can be made both better-tasting and longer-lasting thanks ... "Working with GM tomatoes that are different to normal ... allows us to pinpoint exactly how to breed in ... Innes Centre. , The research could also lead to ... characteristics because even higher levels of the compounds can ...
(Date:5/23/2013)... Laboratory honored more than 165 staff for their ... PNNL,s annual Intellectual Property Commercialization Recognition & Rewards ... national laboratory named materials scientist Jun Liu Inventor ... materials that can store large amounts of energy, ... the time it takes to charge cell phones, ...
Breaking Biology News(10 mins):Frontiers news briefs: May 23 2Frontiers news briefs: May 23 3The world's favorite fruit only better-tasting and longer-lasting 2PNNL staff recognized for scientific accomplishments, moving technologies into the marketplace 2
... Institute, an NCI-designated cancer center at NYU Langone Medical ... Diffuse Large B-Cell Lymphoma (DLBCL), the most aggressive and ... published in the November 23 issue of Nature ... development of lymphomagenesis. "We have discovered that ...
... 28, 2011) -- Scientists at Weill Cornell Medical College used ... specially engineered for the study of cleft lip and cleft ... or treat the conditions in humans. Cleft lip and ... treatment requiring multiple cycles of surgery, speech therapy and orthodontics. ...
... published by Pensoft reported a substantial growth in 2011, ... jubilee 150th issue, By the end of November 2011, the ... compare with 4,962 pages and 180 articles in 2010). Since ... than 19,000 pages and 780 articles of valuable information on ...
Cached Biology News:New potential therapeutic target identified for Diffuse Large B-Cell Lymphoma 2Cleft lip corrected genetically in mouse model 2Cleft lip corrected genetically in mouse model 3Growth through innovations and open access: The journal ZooKeys on point for digital taxonomy 2
... Pichia Protocols is the first all-inclusive ... the Pichia pastoris Expression System. Methods developed ... provided as detailed, step-by-step protocols. This book ... expression vector, through strain construction and analysis, ...
Rad 51C Immunogen: His-tagged human Rad 51C, over-expressed in E. coli Storage: 4 C...
...
...
Biology Products: